What are the potential systemic side effects and dependency risks of the newest FDA approved orexin receptor antagonists for chronic maintenance insomnia?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What are the potential systemic side effects and dependency risks of the newest FDA approved orexin receptor antagonists for chronic maintenance insomnia?
4 real searches · 1 real-search pass
FDA approved dual orexin receptor antagonists daridorexant lemborexant suvorexant prescribing information warnings dependence abuse 2026Google ↗
OBSERVED
Quviviq prescribing information 2025 daridorexant adverse reactions CNS depression complex sleep behaviors dependence withdrawalGoogle ↗
OBSERVED
Dayvigo prescribing information 2025 lemborexant adverse reactions half life abuse dependenceGoogle ↗
OBSERVED
Belsomra prescribing information suvorexant adverse reactions abuse dependence withdrawalGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 4 queries…
Searches and sources
ChatGPT4 real searches · gpt-6
FDA approved dual orexin receptor antagonists daridorexant lemborexant suvorexant prescribing information warnings dependence abuse 2026 Google ↗
Quviviq prescribing information 2025 daridorexant adverse reactions CNS depression complex sleep behaviors dependence withdrawal Google ↗
Dayvigo prescribing information 2025 lemborexant adverse reactions half life abuse dependence Google ↗
Belsomra prescribing information suvorexant adverse reactions abuse dependence withdrawal Google ↗
- These highlights do not include all the information needed to use QUVIVIQ safely and effectively. See full prescribing information for QUVIVIQ. QUVIVIQ (daridorexant) tablets, for oral use, CIV Initial U.S. Approval: 2022 · dailymed.nlm.nih.gov
- label · accessdata.fda.gov
- DailyMed · dailymed.nlm.nih.gov
- These highlights do not include all the information needed to use BELSOMRA safely and effectively. See full prescribing information for BELSOMRA. BELSOMRA® (suvorexant) tablets, for oral use, C-IV Initial U.S. Approval: 2014 · dailymed-beta.nlm.nih.gov
- Beyond traditional sleeping pills: safety, efficacy and multidisease potential of three approved orexin receptor antagonists · pmc.ncbi.nlm.nih.gov
- Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V · thefederalregister.org
- DEPARTMENT OF JUSTICE · public-inspection.federalregister.gov
Queries
4 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
FDA approved dual orexin receptor antagonists daridorexant lemborexant suvorexant prescribing information warnings dependence abuse 2026 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
Quviviq prescribing information 2025 daridorexant adverse reactions CNS depression complex sleep behaviors dependence withdrawal OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
Dayvigo prescribing information 2025 lemborexant adverse reactions half life abuse dependence OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
Belsomra prescribing information suvorexant adverse reactions abuse dependence withdrawal OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |